Sustained polyp burden reduction with DUPIXENT once every 2 weeks3,e,f
SINUS-52

Illustrations of endoscopy adapted from actual patient images. Individual results may vary.

Reduction in bilateral
NPS as early as Week 4,g sustained through
Week 523,e,f

SINUS-52

eNPS at Week 52 in SINUS-52 (key secondary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=150) and placebo + INCS (n=153): -2.40 (95% CI: -2.77, -2.02) (-2.24 from a baseline score of 6.07 vs 0.15 from a baseline score of 5.96, respectively) (P<0.0001).3,4

fNPS at Week 24 in SINUS-52 (coprimary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=295, pooled arms) and placebo + INCS (n=153): -1.80 (95% CI: -2.10, -1.51) (-1.71 from a baseline score of 6.18 vs 0.10 from a baseline score of 5.96, respectively) (P<0.0001).3,4

gNPS at Week 4 in SINUS-52. LSM difference between DUPIXENT 300 mg Q2W + INCS (n=150) and placebo + INCS (n=153): -1.18 (95% CI: -1.47, -0.90) (-1.13 from a baseline score of 6.07 vs 0.05 from a baseline score of 5.96, respectively).3

hNPS at Week 24 in SINUS-52. LSM difference between DUPIXENT 300 mg Q2W + INCS (n=150) and placebo + INCS (n=153): -1.79 (95% CI: -2.13, -1.44) (-1.69 from a baseline score of 6.07 vs 0.09 from a baseline score of 5.96, respectively).3

Nasal polyp score (NPS), the sum of right and left nostril scores (range 0-4 for each nostril, range 0-8 in total) as evaluated by nasal endoscopy: reduced score indicates improvement.4

INCS, intranasal corticosteroids; LSM, least squares mean; Q2W, once every 2 weeks.